SCHEMBL12379697

SCHEMBL12379697

CCOCC1CC2C3CCc4cc(OSOON)ccc4C3CC[C@]2(C)C1=O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 7/20 0.69
MAPT P10636 2/20 0.46
LMNA P02545 1/20 0.46
RECQL P46063 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
STS P08842 7/20 0.45
ESR1 P03372 2/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA4 P22748 1/20 0.45
CA6 P23280 1/20 0.45
CA9 Q16790 1/20 0.45
ESR2 Q92731 1/20 0.45
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 1/20 0.43
ABCC4 O15439 1/20 0.43
CYP2C9 P11712 1/20 0.43
ABCC1 P33527 1/20 0.43
SLCO1B1 Q9Y6L6 1/20 0.43
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12379642 0.82 HSD17B1 (1.00) HSD17B1MAPTLMNASTSESR1
SCHEMBL2289901 0.82 HSD17B1 (1.00) HSD17B1MAPTLMNASTSESR1
SCHEMBL1977506 0.82 HSD17B1 (1.00) HSD17B1MAPTLMNASTSESR1
SCHEMBL12379708 0.82 HSD17B1 (0.66) HSD17B1MAPTLMNARECQLSMN1; SMN2
SCHEMBL10116722 0.80 LMNA (0.70) HSD17B1MAPTLMNARECQLSMN1; SMN2
SCHEMBL13168702 0.80 ESR1 (0.62) HSD17B1MAPTLMNARECQLSMN1; SMN2
SCHEMBL11315779 0.76 HSD17B1 (0.67) HSD17B1MAPTLMNARECQLSMN1; SMN2
SCHEMBL11239229 0.76 HSD17B1 (0.67) HSD17B1MAPTLMNARECQLSMN1; SMN2
SCHEMBL12589516 0.76 STS (0.73) HSD17B1MAPTLMNARECQLSMN1; SMN2
SCHEMBL14375467 0.76 STS (0.71) HSD17B1MAPTLMNARECQLSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003783-B2 Steroid 17 beta -hydroxysteroid dehydrogenase inhibitors substituted with one or more oxime groups, especially aromatase inhibitors used in the treatment of endocrine-dependent tumors, especially breast cancer STERIX LIMITED (GB) 2011-08-23 US disclosed